MeiraGTx Chief Scientific Officer Stuart Naylor sold 27,659 shares for $409,000 on July 7, 2026, at a weighted average price of $14.80 per share. The sale, executed under a Rule 10b5-1 trading plan adopted in December 2025, reduced his direct holdings by 4% to 640,846 shares worth $9.39 million based on the closing price that day. The transaction occurred after the stock returned 89% over the prior year, with the company recently signing a collaboration with Eli Lilly worth $75 million upfront and over $400 million in potential milestones, reacquiring the late-stage eye therapy bota-vec from Johnson & Johnson, and securing FDA Breakthrough Therapy Designation for its dry-mouth gene therapy. CEO Alexandria Forbes stated the company is positioned to file for approval and launch two wholly owned therapies within two years, supported by cash runway into the second half of 2028 following a $100 million raise.
MeiraGTx Holdings PLCInsider sale under 10b5-1 plan is routine; the article highlights positive developments: collaboration with Eli Lilly, reacquisition of bota-vec, FDA Breakthrough Therapy, and cash runway.
Johnson & Johnson
Eli Lilly and Company